Crinetics Pharmaceuticals, Inc. Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc.

CRNX

Classificação em ações #2195
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Preço da ação
$84.95
Última sincronização: 2026-09-01
Valor de mercado
$9.00B
Variação (1 dia)
0.00%
Variação (1 ano)
110.12%
País
US
Negociar Crinetics Pharmaceuticals, Inc. (CRNX)

Categoria

Healthcare
Histórico de preços das ações de Crinetics Pharmaceuticals, Inc. (CRNX)
Preço de fecho mais alto: $84.95 em 2026-09-01

Preço de fecho mais baixo: $24.52 em 2018-07-01
Histórico de preços das ações da Crinetics Pharmaceuticals, Inc. de 2018 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2026 (TTM) 3.89%
2025 -13.25%
2024 59.38%
2023 103.03%
2022 -34.46%
2021 91.75%
2020 -37.94%
2019 -30.68%
2018 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
$535.96 25.68%
US
$186.23 593.59%
US
$137.83 -3.78%
AU
$291.76 2.51%
BE
$892.29 9.59%
NL